Magellan Rx Formulary
Standard and Precision Formulary Updates
Effective January 2021
The Magellan Rx Management Pharmacy & Therapeutics Committee (P&T) and Value Assessment Committee (VAC) meet periodically to review the status of drugs on the formulary and determine updates that are needed due to newly approved products, changes in practice guidelines, updates in FDA approved labeling and/or changes in financial implications. The following is the list of determinations made through this review process for the Magellan Rx Standard and Precision commercial formularies.
New Drugs
REVIEW DATE | LABEL NAME | INDICATIONS | SIMILAR PRODUCTS* | CHANGE TYPE | FORMULARY STATUS | EFFECTIVE DATE |
---|---|---|---|---|---|---|
Jan-21 | CERIANNA 148-3,700 MBQ/ML VIAL | diagnostic imaging | NEW BRAND | NF | Jan-21 | |
Jan-21 | GA 68 PSMA-11 18.5-185 MBQ/ML | diagnostic imaging | NEW GENERIC | NF | Jan-21 | |
Jan-21 | EPHEDRINE 15 MG/3 ML-0.9% NACL | Pressor agent used for allergic disorders | EPHEDRINE SULFATE | NEW GENERIC | NF | Jan-21 |
Jan-21 | PHENYLEPHRINE 300 MG/250 ML-NS | Alpha-1 adrenergic receptor agonist indicated for increasing blood pressure | EMERPHED, EPHEDRINE SULFATE | NEW GENERIC | NF | Jan-21 |
Jan-21 | NOREPINEPH 32 MG/250-0.9% NACL | Blood pressure control in acute hypotensive states | NEW GENERIC | NF | Jan-21 | |
Jan-21 | AVEIDAOXIA 1%-1%-4% GEL | Compounded product-Not FDA approved | IVERMECTIN-METRONIDAZOLE-NIACN | NEW BRAND | NF | Jan-21 |
Jan-21 | CHLOOXIA 0.05%-4% CREAM | Compounded product-Not FDA approved | CLOBETASOL PROPION-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | CHLOOXIA 0.05%-4% OINTMENT | Compounded product-Not FDA approved | CLOBETASOL PROPION-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | CHLOOXIA 0.05%-4% SOLUTION | Compounded product-Not FDA approved | CLOBETASOL PROPION-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DEOXIA 1%-4% GEL | Compounded product-Not FDA approved | CLINDAMYCIN-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DEOXIA 1%-4% LOTION | Compounded product-Not FDA approved | CLINDAMYCIN-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DIADIMAXIA 6%-2%-5% GEL | Compounded product-Not FDA approved | DAPSONE-NIACINAM-SPIRONOLACTON | NEW BRAND | NF | Jan-21 |
Jan-21 | DIAOXIA 6%-4% GEL | Compounded product-Not FDA approved | DAPSONE-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DIASDIMAXIA 8.5%-2%-5% GEL | Compounded product-Not FDA approved | DAPSONE-NIACINAM-SPIRONOLACTON | NEW BRAND | NF | Jan-21 |
Jan-21 | DIASOXIA 8.5%-4% GEL | Compounded product-Not FDA approved | DAPSONE-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DIFMETIOXRIME 4%-2%-1%-4% SOLN | Compounded product-Not FDA approved | FLUCONAZ-IBU-ITRACONAZ-TERBINA | NEW BRAND | NF | Jan-21 |
Jan-21 | DIMOXIA 4%-5% GEL | Compounded product-Not FDA approved | NIACINAMIDE-SPIRONOLACTONE | NEW BRAND | NF | Jan-21 |
Jan-21 | DRAXACE 2%-8% SUSPENSION | Compounded product-Not FDA approved | SALICYLIC ACID-SULFACETAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | DRIXECE 5%-10% SUSPENSION | Topical suspension | SALICYLIC ACID-SULFACETAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | ECEOXIA 4%-10% CREAM | Compounded product-Not FDA approved | NIACINAMIDE-SULFACETAMIDE SOD | NEW BRAND | NF | Jan-21 |
Jan-21 | ETHOXIA 4%-0.05% CREAM | Compounded product-Not FDA approved | NIACINAMIDE-TAZAROTENE | NEW BRAND | NF | Jan-21 |
Jan-21 | HYLAZINC TABLET | mineral deficiency,mineral deficiency prevention,vitamin deficiency,vitamin deficiency prevention | FOLIKA-V,FOLITE | NEW BRAND | NF | Jan-21 |
Jan-21 | IMIOXIA 1%-4% CREAM | Compounded product-Not FDA approved | ECONAZOLE NITRATE-NIACINAMIDE | NEW BRAND | NF | Jan-21 |
Jan-21 | ITHOXIA 4%-0.1% CREAM | Compounded product-Not FDA approved | NIACINAMIDE-TAZAROTENE | NEW BRAND | NF | Jan-21 |
Jan-21 | KATARYA 0.5%-4%-0.025% EMULS | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN,KATARYAXN | NEW BRAND | NF | Jan-21 |
Jan-21 | KATARYAXN 0.5%-4%-0.025% EMULS | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN,KATARYA | NEW BRAND | NF | Jan-21 |
Jan-21 | KAXM 4% EMULSION | Compounded product-Not FDA approved | HYDROQUINONE | NEW BRAND | NF | Jan-21 |
Jan-21 | KEIDO 6% EMULSION | Compounded product-Not FDA approved | HYALURONIC ACID-HYDROQUINONE | NEW BRAND | NF | Jan-21 |
Jan-21 | KETARYA 0.5%-6%-0.025% EMULS | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN | NEW BRAND | NF | Jan-21 |
Jan-21 | KEVARYA 0.5%-6%-0.05% EMULSION | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN | NEW BRAND | NF | Jan-21 |
Jan-21 | KEXM 6% EMULSION | Compounded product-Not FDA approved | HYDROQUINONE | NEW BRAND | NF | Jan-21 |
Jan-21 | KEYA 0.5%-6% EMULSION | Compounded product-Not FDA approved | HYDROCORTISONE-HYDROQUINONE | NEW BRAND | NF | Jan-21 |
Jan-21 | KUTARYAXM 0.5%-8%-0.025% EMULS | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN,KUTARYAXMPA | NEW BRAND | NF | Jan-21 |
Jan-21 | KUTARYAXMPA 0.5%-8%-0.025% | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN,KUTARYAXM | NEW BRAND | NF | Jan-21 |
Jan-21 | KUTEA 8% EMULSION | Compounded product-Not FDA approved | HYDROQUINONE,KUXM | NEW BRAND | NF | Jan-21 |
Jan-21 | KUVARYA 0.5%-8%-0.05% EMULSION | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN | NEW BRAND | NF | Jan-21 |
Jan-21 | KUVARYE 1%-8%-0.05% EMULSION | Compounded product-Not FDA approved | HYDROCORT-HYDROQUINONE-TRETIN | NEW BRAND | NF | Jan-21 |
Jan-21 | KUXM 8% EMULSION | Compounded product-Not FDA approved | HYDROQUINONE,KUTEA | NEW BRAND | NF | Jan-21 |
Jan-21 | PHEODOYO 2.5%-1%-2% CREAM | Compounded product-Not FDA approved | HYDROCORT-IODOQUINOL-KETOCONAZ | NEW BRAND | NF | Jan-21 |
Jan-21 | PHEYO 2.5%-2% CREAM | Compounded product-Not FDA approved | HYDROCORTISONE-KETOCONAZOLE | NEW BRAND | NF | Jan-21 |
Jan-21 | SZOSIL 3.6 CM X 15CM GEL SHEET | Compounded product-Not FDA approved | SILICONE SCAR THERAPY GEL STRP | NEW BRAND | NF | Jan-21 |
Jan-21 | TARDEOXIA 1%-4%-0.025% CREAM | Compounded product-Not FDA approved | CLINDAMY-NIACINAMIDE-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | TARDIMAXIA 2%-5%-0.025% GEL | Compounded product-Not FDA approved | NIACINAM-SPIRONOLACT-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | TAROXIA 4%-0.025% CREAM | Compounded product-Not FDA approved | NIACINAMIDE-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | TAROXIA 4%-0.025% GEL | Compounded product-Not FDA approved | NIACINAMIDE-TRETINOIN | NEW GENERIC | NF | Jan-21 |
Jan-21 | VARDIMAXIA 2%-5%-0.05% GEL | Compounded product-Not FDA approved | NIACINAM-SPIRONOLACT-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | VAROXIA 4%-0.05% CREAM | Compounded product-Not FDA approved | NIACINAMIDE-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | VAROXIA 4%-0.05% GEL | Compounded product-Not FDA approved | NIACINAMIDE-TRETINOIN | NEW BRAND | NF | Jan-21 |
Jan-21 | WESTGEL DHA SOFTGEL | lactating mother,pregnancy | TRISTART DHA | NEW BRAND | NF | Jan-21 |
Jan-21 | LIFEMS NALOXONE 2 MG/2 ML KIT | opiate-induced respiratory depression,opioid overdose | EVZIO,NALOXONE HCL,NARCAN | NEW BRAND | NF | Jan-21 |
Jan-21 | ACETAMINOPHEN 1000MG/100ML BAG | fever,pain,pain treatment adjunct,postoperative acute pain | TYLENOL | NEW GENERIC | GEN | Jan-21 |
Jan-21 | ACETAMINOPHEN 1000MG/100ML VL | fever,pain,pain treatment adjunct,postoperative acute pain | OFIRMEV | NEW GENERIC | GEN | Jan-21 |
Jan-21 | ALVIMOPAN 12 MG CAPSULE | postoperative ileus | ENTEREG | NEW GENERIC | GEN | Jan-21 |
Jan-21 | XARACOLL 100 MG IMPLANT | acute post-op pain following open inguinal hernia repair | BUPIVACAINE | NEW BRAND | NPB | Jan-21 |
Jan-21 | MELOXICAM 10 MG CAPSULE | osteoarthritis | VIVLODEX | NEW GENERIC | GEN | Jan-21 |
Jan-21 | MELOXICAM 5 MG CAPSULE | osteoarthritis | VIVLODEX | NEW GENERIC | GEN | Jan-21 |
Jan-21 | NYMYO 0.25-0.035 MG (28) TAB | acne vulgaris,pregnancy contraception | ORTHO-CYCLEN, PREVIFEM, SPRINTEC | NEW GENERIC | GEN | Jan-21 |
Jan-21 | ICLEVIA 0.15 MG-0.03 MG TABLET | pregnancy contraception | INTROVALE,JOLESSA | NEW GENERIC | GEN | Jan-21 |
Jan-21 | NITAZOXANIDE 500 MG TABLET | giardiasis,infection by Cryptosporidium | ALINIA | NEW GENERIC | GEN | Jan-21 |
Jan-21 | VAXELIS VACCINE SYRINGE | DPT, hepatitis B and polio vaccination,Haemophilus influenzae type b vaccination | TDAP | NEW BRAND | PB | Jan-21 |
Jan-21 | VAXELIS VACCINE VIAL | DPT, hepatitis B and polio vaccination,Haemophilus influenzae type b vaccination | TDAP | NEW BRAND | PB | Jan-21 |
Jan-21 | DIFICID 40 MG/ML SUSPENSION | Clostridioides difficile infection | AZITHROMYCIN, ERYTHROMYCIN | NEW FORMULATION | NPB | Jan-21 |
Jan-21 | HYCODAN 5 MG-1.5 MG/5 ML SOLN | cough | HYDROCODONE-HOMATROPINE MBR, HYDROMET | NEW BRAND | NPB | Jan-21 |
Jan-21 | RETACRIT 20,000 UNIT/ML VIAL | anemia due to chemotherapy and radiotherapy combination,anemia in chronic kidney disease,chemotherapy-induced anemia,reduction of allogeneic blood transfusion in surgery,zidovudine-induced anemia | ARANESP,EPOGEN,MIRCERA,PROCRIT | NEW STRENGTH | PS | Jan-21 |
Jan-21 | OXYTOCIN ACETATE POWDER | bulk powder for compounding | NEW GENERIC | NPB | Jan-21 | |
Jan-21 | IVERMECTIN 0.5% LOTION | pediculosis capitis,pediculosis prevention | SKLICE | NEW GENERIC | GEN | Jan-21 |
Jan-21 | DANYELZA 40 MG/10 ML VIAL | high-risk neuroblastoma in bone or bone marrow | UNITUXIN | NEW BRAND | NPS | Jan-21 |
Jan-21 | ORLADEYO 110 MG CAPSULE | prevention of angioedema attack in hereditary angioedema | KALBITOR,TAKHZYRO | NEW BRAND | NPS | Jan-21 |
Jan-21 | ORLADEYO 150 MG CAPSULE | prevention of angioedema attack in hereditary angioedema | KALBITOR,TAKHZYRO | NEW BRAND | NPS | Jan-21 |
Jan-21 | OXLUMO 94.5 MG/0.5 ML VIAL | primary hyperoxaluria type I | NEW BRAND | NF | Jan-21 | |
Jan-21 | TRETINOIN GEL MICRO 0.1% PUMP | acne vulgaris | RETIN-A MICRO PUMP | DRUG CHANGES | NPB | Jan-21 |
Jan-21 | LEVOTHYROXINE 13 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 25 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 50 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 75 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 88 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 100 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 112 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 125 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 137 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 150 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 175 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Jan-21 | LEVOTHYROXINE 200 MCG CAPSULE | adjunct to surgery or radiotherapy for thyroid carcinoma,hypothyroidism | TIROSINT | DRUG CHANGES | NF | Jan-21 |
Value Assessment Committee Highlights
REVIEW DATE | LABEL NAME | INDICATIONS | SIMILAR PRODUCTS* | CHANGE TYPE | FORMULARY STATUS | EFFECTIVE DATE |
---|---|---|---|---|---|---|
Jan-21 | AVSOLA 100 MG VIAL | Crohn's disease,ankylosing spondylitis,moderate to severe plaque psoriasis,psoriatic arthritis,rheumatoid arthritis,ulcerative colitis | REMICADE, RENFLEXIS, INFLECTRA | DRUG CHANGES | NF-->PS | Jan-21 |
Jan-21 | RENFLEXIS 100 MG VIAL | Crohn's disease,ankylosing spondylitis,moderate to severe plaque psoriasis,psoriatic arthritis,rheumatoid arthritis,ulcerative colitis | REMICADE, INFLECTRA, AVSOLA | DRUG CHANGES | PS --> NF | Jan-21 |
Jan-21 | UDENYCA 6 MG/0.6 ML SYRINGE | prevention of neutropenia from cancer chemotherapy | NEULTASTA, NEULASTA ONPRO | DRUG CHANGES | NPS-->PS | Jan-21 |
Jan-21 | NEULASTA 6 MG/0.6 ML SYRINGE | hematopoietic syndrome of acute radiation syndrome,prevention of neutropenia from cancer chemotherapy | NEULASTA ONPRO | DRUG CHANGES | NPS-->PS | Jan-21 |
Jan-21 | NEULASTA ONPRO 6 MG/0.6 ML KIT | hematopoietic syndrome of acute radiation syndrome,prevention of neutropenia from cancer chemotherapy | NEULASTA, UDENYCA | DRUG CHANGES | NPS-->PS | Jan-21 |
Jan-21 | ABIRATERONE 500 MG TABLET | metastatic castration-resistant prostate cancer,metastatic castration-sensitive prostate cancer | ZYTIGA | NEW GENERIC | NF | Jan-21 |
Jan-21 | ASENAPINE 10 MG TABLET SL | mania associated with bipolar disorder,mixed bipolar I disorder,schizophrenia | SAPHRIS | NEW GENERIC | NF | Jan-21 |
Jan-21 | ASENAPINE 2.5 MG TABLET SL | mania associated with bipolar disorder,mixed bipolar I disorder,schizophrenia | SAPHRIS | NEW GENERIC | NF | Jan-21 |
Jan-21 | ASENAPINE 5 MG TABLET SL | mania associated with bipolar disorder,mixed bipolar I disorder,schizophrenia | SAPHRIS | NEW GENERIC | NF | Jan-21 |
Jan-21 | ORTIKOS ER 6 MG CAPSULE | Crohn's disease | BUDESONIDE EC | DRUG CHANGES | NF | Jan-21 |
Jan-21 | ORTIKOS ER 9 MG CAPSULE | Crohn's disease | BUDESONIDE EC | DRUG CHANGES | NF | Jan-21 |
Jan-21 | TWIRLA 120-30 MCG/DAY PATCH | pregnancy contraception | LEVONEST,LEVONORGESTREL-ETH | DRUG CHANGES | NPB-->NF | Jan-21 |
Jan-21 | ARAZLO 0.045% LOTION | acne vulgaris | FABIOR,TAZAROTENE,TAZORAC | DRUG CHANGES | NF | Jan-21 |
Jan-21 | FABIOR 0.1% FOAM | acne vulgaris,psoriasis | ARAZLO,TAZAROTENE,TAZORAC | DRUG CHANGES | NPB-->NF | Jan-21 |
Jan-21 | PHEXXI 1.8-1-0.4% VAGINAL GEL | pregnancy contraception | OTC SPERMICIDE | DRUG CHANGES | NPB-->NF | Jan-21 |
Jan-21 | TAZORAC 0.05% CREAM | psoriasis | ARAZLO,FABIOR,TAZAROTENE | DRUG CHANGES | NPB-->NF | Jan-21 |
Jan-21 | TAZORAC 0.05% GEL | psoriasis | ARAZLO,FABIOR,TAZAROTENE | DRUG CHANGES | NPB-->NF | Jan-21 |
Jan-21 | TAZORAC 0.1% GEL | acne vulgaris,psoriasis | ARAZLO,FABIOR,TAZAROTENE | DRUG CHANGES | NPB-->NF | Jan-21 |
Formulary Key
ABBREVIATION | DEFINITION |
---|---|
GEN | Generic |
GEN (SP) | Generic (Specialty) |
PB | Preferred Brand |
NPB | Non-Preferred Brand |
PS | Preferred Specialty |
NPS/SP | Non-Preferred Specialty/Specialty |
NF | Non-Formulary |
QL | Quantity Limit |
GL | Gender Limit |
ST | Step Therapy |
PA | Prior Authorization |
MED | Medical Flag |
BSP | Benefit Shift Program |
NFDA | Non-FDA Approved |
* | Manage consistent with other drugs in class, unless otherwise specified |
ª | Clinically similar products |